KR20020080413A - 알파-2비-아르레노셉터에 의해서 매개된 질병의 치료 또는예방에 유용한 화합물 - Google Patents

알파-2비-아르레노셉터에 의해서 매개된 질병의 치료 또는예방에 유용한 화합물 Download PDF

Info

Publication number
KR20020080413A
KR20020080413A KR1020027010329A KR20027010329A KR20020080413A KR 20020080413 A KR20020080413 A KR 20020080413A KR 1020027010329 A KR1020027010329 A KR 1020027010329A KR 20027010329 A KR20027010329 A KR 20027010329A KR 20020080413 A KR20020080413 A KR 20020080413A
Authority
KR
South Korea
Prior art keywords
alpha
disease
adrenoceptor
mammal
compounds
Prior art date
Application number
KR1020027010329A
Other languages
English (en)
Korean (ko)
Inventor
시에그프리에드 우르스테르
미아 엥그스트룀
리사 후오비넨
사리 칼리오코스키
레이라 켈라네
에바-리사 사보라
Original Assignee
오와이 주반티아 팔마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20000303A external-priority patent/FI20000303A0/fi
Application filed by 오와이 주반티아 팔마 리미티드 filed Critical 오와이 주반티아 팔마 리미티드
Publication of KR20020080413A publication Critical patent/KR20020080413A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020027010329A 2000-02-11 2001-02-07 알파-2비-아르레노셉터에 의해서 매개된 질병의 치료 또는예방에 유용한 화합물 KR20020080413A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18202100P 2000-02-11 2000-02-11
US60/182,021 2000-02-11
FI20000303A FI20000303A0 (fi) 2000-02-14 2000-02-14 Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
FI20000303 2000-02-14
PCT/FI2001/000105 WO2001058454A1 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor

Publications (1)

Publication Number Publication Date
KR20020080413A true KR20020080413A (ko) 2002-10-23

Family

ID=26160944

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027010329A KR20020080413A (ko) 2000-02-11 2001-02-07 알파-2비-아르레노셉터에 의해서 매개된 질병의 치료 또는예방에 유용한 화합물

Country Status (22)

Country Link
EP (1) EP1253926A1 (es)
JP (1) JP2003522148A (es)
KR (1) KR20020080413A (es)
AU (1) AU780802B2 (es)
BR (1) BR0108221A (es)
CA (1) CA2399421A1 (es)
CZ (1) CZ20022884A3 (es)
EA (1) EA200200846A1 (es)
EE (1) EE200200435A (es)
GE (1) GEP20043356B (es)
HR (1) HRP20020746A2 (es)
HU (1) HUP0300032A3 (es)
IL (1) IL151017A0 (es)
IS (1) IS6476A (es)
MX (1) MXPA02007454A (es)
MY (1) MY133957A (es)
NO (1) NO20023773D0 (es)
NZ (1) NZ520500A (es)
PL (1) PL357872A1 (es)
SK (1) SK11472002A3 (es)
WO (1) WO2001058454A1 (es)
YU (1) YU59102A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000615A (es) * 2001-07-20 2004-04-20 Juvantia Pharma Ltd Oy Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor.
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416432D0 (en) * 1984-06-28 1984-08-01 Wyeth John & Brother Ltd Benzoquinolizines
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents

Also Published As

Publication number Publication date
AU780802B2 (en) 2005-04-21
EE200200435A (et) 2003-12-15
HUP0300032A2 (en) 2003-05-28
EA200200846A1 (ru) 2002-12-26
CZ20022884A3 (cs) 2003-02-12
WO2001058454A1 (en) 2001-08-16
GEP20043356B (en) 2004-04-13
EP1253926A1 (en) 2002-11-06
HRP20020746A2 (en) 2004-12-31
BR0108221A (pt) 2003-03-05
HUP0300032A3 (en) 2006-01-30
AU3551001A (en) 2001-08-20
NZ520500A (en) 2005-01-28
MY133957A (en) 2007-11-30
JP2003522148A (ja) 2003-07-22
YU59102A (sh) 2005-11-28
CA2399421A1 (en) 2001-08-16
SK11472002A3 (sk) 2003-02-04
NO20023773L (no) 2002-08-09
IL151017A0 (en) 2003-02-12
PL357872A1 (en) 2004-07-26
NO20023773D0 (no) 2002-08-09
MXPA02007454A (es) 2004-08-23
IS6476A (is) 2002-07-19

Similar Documents

Publication Publication Date Title
Pflueger et al. Role of adenosine in contrast media—induced acute renal failure in diabetes mellitus
Shahid et al. Tumor necrosis factor-α induces renal vasoconstriction as well as natriuresis in mice
Frishman et al. Calcium entry blockers for the treatment of severe hypertension and hypertensive crisis
Su et al. Role of the central renin‑angiotensin system in hypertension
WO2010081817A1 (en) Method for treating colorectal cancer
Mizobe et al. α2-Adrenoceptor agonists and anesthesia
ES2655881T3 (es) 2,4,6-Trifluoro-N-[6-(1-metil-piperidin-4-carbonil)-piridin-2-il]-benzamida para el tratamiento de la migraña a través de la vía oral o intravenosa
Stover et al. Effects of tacrolimus on hemispheric water content and cerebrospinal fluid levels of glutamate, hypoxanthine, interleukin-6, and tumor necrosis factor-α following controlled cortical impact injury in rats
KR20090032083A (ko) 신장 기능이 손상된 개체의 이뇨 작용 개선 방법
Esler Effect of practolol on blood pressure and renin release in man
Gurbanov et al. Bosentan improves renal regional blood flow in rats with experimental congestive heart failure
Leenen et al. Central sympathoinhibitory effects of calcium channel blockers
KR20020080413A (ko) 알파-2비-아르레노셉터에 의해서 매개된 질병의 치료 또는예방에 유용한 화합물
JPH09221423A (ja) 薬物依存形成抑制剤
ES2322954T3 (es) Agonistas del adrenoceptor alfa 2b o 2b/2c para el tratamiento de la enfermedad de alzheimer y la enfermedad de parkinson.
Romanovsky et al. Peripheral naloxone attenuates lipopolysaccharide fever in guinea pigs by an action outside the blood-brain barrier
US6521632B2 (en) Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor
Lynch et al. Opiate modulation of IL-1α, IL-2, and TNF-α transport across the blood–brain barrier
Laurent et al. Rilmenidine: a novel approach to first-line treatment of hypertension
KR20230050363A (ko) 질환의 치료에 있어서 btk 저해제의 용도
Salonen et al. Clinical interactions with alpha-2-adrenergic agonists in anesthetic practice
Quadri et al. Recent advances in antihypertensive therapy
REID New therapeutic agents for hypertension
Dinakar Comparative study of variations in blood pressure and heart rate among normotensive patients and hypertensive patients receiving angiotensin receptor blockers during surgery under spinal anesthesia
Aceto The antinicotinic effects of drugs with clinically useful sedative-antianxiety properties

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application